Login / Signup

Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer.

Jesse A SussellJoshua A RothCraig S MeyerAnita FungSvenn A Hansen
Published in: Advances in therapy (2022)
Dual targeted therapy via FDC (with transition to T-DM1 in the case of RD) is a cost-effective treatment strategy in high-risk HER2+ ESBC.
Keyphrases
  • early stage
  • type diabetes
  • rectal cancer
  • metabolic syndrome
  • skeletal muscle
  • insulin resistance
  • cancer therapy
  • replacement therapy